Takeda's Entyvio Beats Humira In Head-To-Head Ulcerative Colitis Trial
Takeda’s gut-selective biologic vedolizumab pushes ahead of other biologics in the race to make its mark in ulcerative colitis, a therapeutic sector targeted by numerous new investigational therapies.
You may also be interested in...
The Institute for Clinical and Economic Review has a full agenda planned for 2020, starting with potential new oral drugs for migraine.
The first real indications of how Shire is contributing to Takeda will come when the Japanese firm issues its annual results next week, and investors will also be keeping a keen eye on the critical first forward guidance for the combined company.
Takeda saw continued growth for mainstay drugs in what it described as a ‘robust’ last quarter of reporting before the inclusion of Shire, with global blockbuster Entyvio leading the way, but gave away little new on widely anticipated post-deal divestments.